董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joon Kim | 男 | Director | 56 | 0.99万美元 | 未持股 | 2022-10-31 |
| Herbert Kim Lyerly | 男 | Director | 64 | 24.05万美元 | 未持股 | 2022-10-31 |
| Kevin R. Smith | 男 | Director | 51 | 5.49万美元 | 未持股 | 2022-10-31 |
| Chao Zhou | 男 | Director | 33 | 5.49万美元 | 未持股 | 2022-10-31 |
| Linda Shi | 女 | Chair of the Board | 58 | 未披露 | 未持股 | 2022-10-31 |
| Robert H. Arch | 男 | Director, President and Chief Executive Officer | 56 | 58.83万美元 | 未持股 | 2022-10-31 |
| Stephany Foster | 女 | Director | 44 | 未披露 | 未持股 | 2022-10-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert H. Arch | 男 | Director, President and Chief Executive Officer | 56 | 58.83万美元 | 未持股 | 2022-10-31 |
| George Chi | 男 | Chief Financial Officer | 53 | 16.57万美元 | 未持股 | 2022-10-31 |
董事简历
中英对照 | 中文 | 英文- Joon Kim
-
Joon Kim自2018年12月起担任董事会成员。Kim先生是一位有成就的诉讼律师，在商业和刑事诉讼事务方面拥有丰富的经验。作为Lee&Ko&8217；的国际诉讼和纠纷解决以及白领犯罪实践集团的合伙人，Kim先生就广泛的诉讼和纠纷解决事项为国内和国际客户提供建议。此外，Kim先生在加州担任检察官，在刑事诉讼中代表加州人民。在此职位上，Kim先生首先主持了陪审团和非陪审团审判，并接受了诉讼各个方面的培训。在担任检察官期间，Kim先生还有在大韩民国司法部主持下的司法研究所担任研究员的经验，在那里他与韩国检察官密切合作。Kim先生在伯克利法学院（Berkeley School of Law）获得法学博士学位，在伯克利商学院（Berkeley School of Business）获得学士学位。
Joon Kim has served on Oncosec Medical Incorporated's Board since December 2018. Mr. Kim is an accomplished litigator with extensive experience in both business and criminal litigation matters. With a particularly strong background in representing clients in court proceedings, Mr. Kim has a comprehensive understanding of every stage of the litigation process, including all aspects of initial investigatory/discovery proceedings, settlement negotiations, contested hearings, pretrial and trial motions, evidentiary issues, trials, and the handling of post-judgment challenges and appeals. Mr. Kim advises corporate clients of varying sizes on a variety of subject matters, inclusive of assisting the top management with strategic decision-making. Mr. Kim has acted as an advisor to Alpha Holdings, Co., Ltd. since July 2018. - Joon Kim自2018年12月起担任董事会成员。Kim先生是一位有成就的诉讼律师，在商业和刑事诉讼事务方面拥有丰富的经验。作为Lee&Ko&8217；的国际诉讼和纠纷解决以及白领犯罪实践集团的合伙人，Kim先生就广泛的诉讼和纠纷解决事项为国内和国际客户提供建议。此外，Kim先生在加州担任检察官，在刑事诉讼中代表加州人民。在此职位上，Kim先生首先主持了陪审团和非陪审团审判，并接受了诉讼各个方面的培训。在担任检察官期间，Kim先生还有在大韩民国司法部主持下的司法研究所担任研究员的经验，在那里他与韩国检察官密切合作。Kim先生在伯克利法学院（Berkeley School of Law）获得法学博士学位，在伯克利商学院（Berkeley School of Business）获得学士学位。
- Joon Kim has served on Oncosec Medical Incorporated's Board since December 2018. Mr. Kim is an accomplished litigator with extensive experience in both business and criminal litigation matters. With a particularly strong background in representing clients in court proceedings, Mr. Kim has a comprehensive understanding of every stage of the litigation process, including all aspects of initial investigatory/discovery proceedings, settlement negotiations, contested hearings, pretrial and trial motions, evidentiary issues, trials, and the handling of post-judgment challenges and appeals. Mr. Kim advises corporate clients of varying sizes on a variety of subject matters, inclusive of assisting the top management with strategic decision-making. Mr. Kim has acted as an advisor to Alpha Holdings, Co., Ltd. since July 2018.
- Herbert Kim Lyerly
-
Herbert Kim Lyerly是杜克大学（Duke University）的乔治·巴斯·盖勒（George Barth Geller）癌症研究教授、外科、免疫学和病理学教授和外科科学应用治疗学科主任，以及杜克综合癌症中心前主任。他是国际公认的癌症治疗和免疫疗法专家，发表了超过300篇科学文章和书籍章节，并编辑了十本外科手术、癌症免疫疗法和新型癌症疗法的教科书。他任职于12个科学期刊的编辑委员会。Lyerly博士于2008年被总统乔治·W·布什（George W.Bush）任命为国家癌症咨询委员会成员，该委员会监督国家癌症研究所，他在该机构任职至2014年。他曾担任癌症中心（Cancer Center）的小组委员会主席，并任职于国家癌症咨询委员会（National Cancer Advisory Board）的全球健康小组委员会。他曾任职于美国国立卫生研究院（National Institutes of Health&NIH&；NIH&；8221；Council），以及NIH艾滋病研究办公室的董事会。他也曾一直担任Susan G.Komen Foundation、the Burroughs Welcome Foundation的科学顾问委员会的成员。他是一个备受追捧的顾问和顾问，并曾任职the Cancer Center&8217；的密歇根大学、芝加哥大学、阿拉巴马大学、亚利桑那大学、波士顿大学和普渡大学的安德森癌症中心的外部顾问委员会。他曾担任the University of Washington和Case Western Reserve Clinical and Translational Science Institutes的顾问。
Herbert Kim Lyerly from April 2017 to March 2020 as a partner in Lee & Ko’s International Litigation and Dispute Resolution and White Collar Crime Practice Groups, Mr. Kim advised clients, both domestic and international, on a broad range of litigation and dispute-resolution matters. In addition, Mr. Kim served as a public prosecutor in California, representing the People of the State of California in criminal proceedings. In that capacity, Mr. Kim has first-chaired both jury and non-jury trials, and has been trained in all aspects of litigation. During his time as a public prosecutor, Mr. Kim also had the experience of serving as a research fellow at the Institute of Justice, under the auspices of the Ministry of Justice of the Republic of Korea, where he worked closely with Korean public prosecutors. Mr. Kim received his J.D. from Berkeley School of Law and his B.S. from the Berkeley School of Business.Dr. Herbert Kim Lyerly, M.D., is the George Barth Geller Professor of Cancer Research from 2004 Professor of Surgery (from 1997), Immunology (from 2017) and Pathology (from 2018), and Director of the Surgical Sciences Applied Therapeutics section at Duke University (from 2021), and former Director of the Duke Comprehensive Cancer Center, a position he held from 2003 to 2011. He is an internationally recognized expert in cancer therapy and immunotherapy, has published over 300 scientific articles and book chapters, and has edited ten textbooks on surgery, cancer immunotherapy and novel cancer therapies. He serves on the editorial board of 12 scientific journals.Dr. Lyerly was appointed in 2008 by President George W. Bush to serve on the National Cancer Advisory Board, which oversees the National Cancer Institute, where he served until 2014. He has served as Chair of the Cancer Center’s Subcommittee and served on the Global Health Subcommittee of the National Cancer Advisory Board. He has served on the National Institutes of Health ("NIH") Council of Councils, and on the board of the NIH Office of AIDS Research. He has also been a member of the scientific advisory boards of the Susan G. Komen Foundation and the Burroughs Welcome Foundation. He is a highly sought-after consultant and advisor and has served on the Cancer Center’s external advisory boards for the M.D. Anderson Cancer Center, University of Michigan, University of Chicago, University of Alabama, University of Arizona, Boston University and Purdue University. He has served as an advisor to the University of Washington and Case Western Reserve Clinical and Translational Science Institutes. - Herbert Kim Lyerly是杜克大学（Duke University）的乔治·巴斯·盖勒（George Barth Geller）癌症研究教授、外科、免疫学和病理学教授和外科科学应用治疗学科主任，以及杜克综合癌症中心前主任。他是国际公认的癌症治疗和免疫疗法专家，发表了超过300篇科学文章和书籍章节，并编辑了十本外科手术、癌症免疫疗法和新型癌症疗法的教科书。他任职于12个科学期刊的编辑委员会。Lyerly博士于2008年被总统乔治·W·布什（George W.Bush）任命为国家癌症咨询委员会成员，该委员会监督国家癌症研究所，他在该机构任职至2014年。他曾担任癌症中心（Cancer Center）的小组委员会主席，并任职于国家癌症咨询委员会（National Cancer Advisory Board）的全球健康小组委员会。他曾任职于美国国立卫生研究院（National Institutes of Health&NIH&；NIH&；8221；Council），以及NIH艾滋病研究办公室的董事会。他也曾一直担任Susan G.Komen Foundation、the Burroughs Welcome Foundation的科学顾问委员会的成员。他是一个备受追捧的顾问和顾问，并曾任职the Cancer Center&8217；的密歇根大学、芝加哥大学、阿拉巴马大学、亚利桑那大学、波士顿大学和普渡大学的安德森癌症中心的外部顾问委员会。他曾担任the University of Washington和Case Western Reserve Clinical and Translational Science Institutes的顾问。
- Herbert Kim Lyerly from April 2017 to March 2020 as a partner in Lee & Ko’s International Litigation and Dispute Resolution and White Collar Crime Practice Groups, Mr. Kim advised clients, both domestic and international, on a broad range of litigation and dispute-resolution matters. In addition, Mr. Kim served as a public prosecutor in California, representing the People of the State of California in criminal proceedings. In that capacity, Mr. Kim has first-chaired both jury and non-jury trials, and has been trained in all aspects of litigation. During his time as a public prosecutor, Mr. Kim also had the experience of serving as a research fellow at the Institute of Justice, under the auspices of the Ministry of Justice of the Republic of Korea, where he worked closely with Korean public prosecutors. Mr. Kim received his J.D. from Berkeley School of Law and his B.S. from the Berkeley School of Business.Dr. Herbert Kim Lyerly, M.D., is the George Barth Geller Professor of Cancer Research from 2004 Professor of Surgery (from 1997), Immunology (from 2017) and Pathology (from 2018), and Director of the Surgical Sciences Applied Therapeutics section at Duke University (from 2021), and former Director of the Duke Comprehensive Cancer Center, a position he held from 2003 to 2011. He is an internationally recognized expert in cancer therapy and immunotherapy, has published over 300 scientific articles and book chapters, and has edited ten textbooks on surgery, cancer immunotherapy and novel cancer therapies. He serves on the editorial board of 12 scientific journals.Dr. Lyerly was appointed in 2008 by President George W. Bush to serve on the National Cancer Advisory Board, which oversees the National Cancer Institute, where he served until 2014. He has served as Chair of the Cancer Center’s Subcommittee and served on the Global Health Subcommittee of the National Cancer Advisory Board. He has served on the National Institutes of Health ("NIH") Council of Councils, and on the board of the NIH Office of AIDS Research. He has also been a member of the scientific advisory boards of the Susan G. Komen Foundation and the Burroughs Welcome Foundation. He is a highly sought-after consultant and advisor and has served on the Cancer Center’s external advisory boards for the M.D. Anderson Cancer Center, University of Michigan, University of Chicago, University of Alabama, University of Arizona, Boston University and Purdue University. He has served as an advisor to the University of Washington and Case Western Reserve Clinical and Translational Science Institutes.
- Kevin R. Smith
-
KevinR.Smith目前是Sirtex Medical US Holdings，Inc.的首席执行官。他结合了医疗器械行业20多年的销售与市场营销经验和企业家的敏锐直觉。在被任命为首席执行官之前，史密斯先生是Sirtex公司负责美洲销售和市场营销的执行Vice President。在加入Sirtex之前，Smith先生是Gel-E，Inc.业务发展的执行Vice President，该公司总部设在马里兰大学，专门从事先进材料止血产品。他曾担任Sensium梦百合公司的首席商务官，以及Teleflex公司的全球销售和营销Vice President，在那里他曾担任公司心脏业务部门的高级销售与市场营销执行官。Kevin持有the University of Phoenix全球管理工商管理硕士学位和the University of Kentucky市场营销理学学士学位。
Kevin R. Smith is currently the Chief Executive Officer and Executive Director of Sirtex Medical Oncosec Medical Incorporated Holdings, Inc. "Sirtex", a position that he has held since October 2019. Mr. Smith served as the interim Chief Executive Officer of OncoSec from February 2022 to May 2022. He combines more than 20 years of sales and marketing experience in the medical device industry with the keen instincts of an entrepreneur. Prior to his appointment to Chief Executive Officer of Sirtex, Mr. Smith served as Sirtex’s interim Chief Executive Officer from April 2019 to October 2019 and Executive Vice President of Sales & Marketing, Americas from August 2017 to April 2019. Before joining Sirtex, Mr. Smith was Executive Vice President of Business Development at Gel-e, Inc., a company based at the University of Maryland specializing in advanced material hemostasis products, a position he held since January 2017. Mr. Smith’s previous positions include Chief Commercial Officer of Sensium Healthcare along with Global Vice President of Sales & Marketing at Teleflex, where he was the senior sales and marketing executive in the company’s cardiac business unit. Mr. Smith holds a Master of Business Administration in Global Management from the University of Phoenix and a Bachelor of Science in Marketing from the University of Kentucky. - KevinR.Smith目前是Sirtex Medical US Holdings，Inc.的首席执行官。他结合了医疗器械行业20多年的销售与市场营销经验和企业家的敏锐直觉。在被任命为首席执行官之前，史密斯先生是Sirtex公司负责美洲销售和市场营销的执行Vice President。在加入Sirtex之前，Smith先生是Gel-E，Inc.业务发展的执行Vice President，该公司总部设在马里兰大学，专门从事先进材料止血产品。他曾担任Sensium梦百合公司的首席商务官，以及Teleflex公司的全球销售和营销Vice President，在那里他曾担任公司心脏业务部门的高级销售与市场营销执行官。Kevin持有the University of Phoenix全球管理工商管理硕士学位和the University of Kentucky市场营销理学学士学位。
- Kevin R. Smith is currently the Chief Executive Officer and Executive Director of Sirtex Medical Oncosec Medical Incorporated Holdings, Inc. "Sirtex", a position that he has held since October 2019. Mr. Smith served as the interim Chief Executive Officer of OncoSec from February 2022 to May 2022. He combines more than 20 years of sales and marketing experience in the medical device industry with the keen instincts of an entrepreneur. Prior to his appointment to Chief Executive Officer of Sirtex, Mr. Smith served as Sirtex’s interim Chief Executive Officer from April 2019 to October 2019 and Executive Vice President of Sales & Marketing, Americas from August 2017 to April 2019. Before joining Sirtex, Mr. Smith was Executive Vice President of Business Development at Gel-e, Inc., a company based at the University of Maryland specializing in advanced material hemostasis products, a position he held since January 2017. Mr. Smith’s previous positions include Chief Commercial Officer of Sensium Healthcare along with Global Vice President of Sales & Marketing at Teleflex, where he was the senior sales and marketing executive in the company’s cardiac business unit. Mr. Smith holds a Master of Business Administration in Global Management from the University of Phoenix and a Bachelor of Science in Marketing from the University of Kentucky.
- Chao Zhou
-
Chao Zhou目前担任广汇医药和梦百合控股有限公司（China Grand Pharmaceutical and Hong Kong Holdings Limited）的执行副总裁，该公司是一家在香港交易所上市的上市公司，向在中国具有丰富研发和产品商业化经验的零售商和医疗机构制造和分销药品和医疗器械。自2018年以来，周先生一直担任新加坡公司Grand Pharma Sphere Pty Ltd，澳大利亚全球医疗器械公司Sirtex Medical Pty Ltd.和Cloudbreak Pharmaceutical Inc.的董事会成员，一家位于开曼群岛的公司，从事生物制药产品的研究，开发，制造和商业化业务。在担任常务副主任之前，周先生曾担任广汇企业有限公司法律安全部的管理董事，广汇企业有限公司是一家投资公司，从事医药和梦百合、商品贸易、房地产投资等业务的运营和管理，金融服务和其他部门。他在中国海洋大学（Ocean University of China）获得法学学士学位，在对外经济贸易大学（University of对外经济贸易大学）获得国际法硕士学位。
Chao Zhou is currently the Chief Executive Officer of Grand Pharmaceutical Group Limited, a public company listed on the Hong Kong stock exchange that develops, manufactures and distributes pharmaceutical products and medical devices to retailers and medical organizations with significant experience in research and development and product commercialization in China, a position he has held since June 2021. Since 2018 Mr. Zhou has served on the Board of Directors of Grand Pharma Sphere Pte. Ltd, a Singapore based company, Sirtex Medical Pty Ltd., the Australian based global medical device company and Cloudbreak Pharmaceutical Inc., a Cayman Islands based company which is engaged in the business of the research, development, manufacturing and commercialization of biopharmaceutical product. Prior to his role as Chief Executive Officer of Grand Pharmaceutical Group Limited, from 2013 Mr. Zhou served as a Management Director in the Department of Legal Security for China Grand Enterprises, Inc., an investment company engaged in the operation and management of businesses covering pharmaceuticals and healthcare, commodity trading, real estate investment, financial service and other sectors. He earned his Bachelor in Law from Ocean University of China and a Master in International Law from the University of International Business and Economics. - Chao Zhou目前担任广汇医药和梦百合控股有限公司（China Grand Pharmaceutical and Hong Kong Holdings Limited）的执行副总裁，该公司是一家在香港交易所上市的上市公司，向在中国具有丰富研发和产品商业化经验的零售商和医疗机构制造和分销药品和医疗器械。自2018年以来，周先生一直担任新加坡公司Grand Pharma Sphere Pty Ltd，澳大利亚全球医疗器械公司Sirtex Medical Pty Ltd.和Cloudbreak Pharmaceutical Inc.的董事会成员，一家位于开曼群岛的公司，从事生物制药产品的研究，开发，制造和商业化业务。在担任常务副主任之前，周先生曾担任广汇企业有限公司法律安全部的管理董事，广汇企业有限公司是一家投资公司，从事医药和梦百合、商品贸易、房地产投资等业务的运营和管理，金融服务和其他部门。他在中国海洋大学（Ocean University of China）获得法学学士学位，在对外经济贸易大学（University of对外经济贸易大学）获得国际法硕士学位。
- Chao Zhou is currently the Chief Executive Officer of Grand Pharmaceutical Group Limited, a public company listed on the Hong Kong stock exchange that develops, manufactures and distributes pharmaceutical products and medical devices to retailers and medical organizations with significant experience in research and development and product commercialization in China, a position he has held since June 2021. Since 2018 Mr. Zhou has served on the Board of Directors of Grand Pharma Sphere Pte. Ltd, a Singapore based company, Sirtex Medical Pty Ltd., the Australian based global medical device company and Cloudbreak Pharmaceutical Inc., a Cayman Islands based company which is engaged in the business of the research, development, manufacturing and commercialization of biopharmaceutical product. Prior to his role as Chief Executive Officer of Grand Pharmaceutical Group Limited, from 2013 Mr. Zhou served as a Management Director in the Department of Legal Security for China Grand Enterprises, Inc., an investment company engaged in the operation and management of businesses covering pharmaceuticals and healthcare, commodity trading, real estate investment, financial service and other sectors. He earned his Bachelor in Law from Ocean University of China and a Master in International Law from the University of International Business and Economics.
- Linda Shi
-
施琳达医学博士是远大医药中国有限公司（Grand Pharma）的副总裁兼首席医疗官，同时也是香港上市公司远大医药集团有限公司的执行董事。在2019年加入Grand Pharma之前，施博士在比利时杨森研发公司担任神经科学全球监管事务（GRA）欧盟监管负责人超过12年，在学术和制药行业拥有超过30年的临床和研究经验，具有与全球多功能矩阵团队合作推动复杂项目的丰富经验。她领导了欧洲和美国的各种临床试验申请（临床试验申请（CTA）和研究性新药申请（IND）），特别是与创新研究路径的首次人体临床试验的战略评估有关。施博士在中国获得医学博士学位，同时在布鲁塞尔自由大学获得医学博士学位。她被任命为全球多所大学的客座教授和客座研究员。
Linda Shi M.D., Ph.D., is the deputy president and Chief Medical officer of Grand Pharma China Co. Ltd. (Grand Pharma), as well as an Executive Director of Grand Pharmaceutical Group Limited, a publicly listed company in Hong Kong. Prior to joining Grand Pharma in 2019 Dr. Shi was the EU Regulatory Leader in the Global Regulatory Affairs (GRA) for Neuroscience at Janssen R&D in Belgium for more than 12 years.has over 30 years of clinical and research experience in academic settings and the pharmaceutical industry, with significant experience working with global multifunctional matrixed teams to drive forward complex projects. She led various applications for clinical trials (Clinical Trial Applications (CTA) and Investigational New Drug Applications (IND)) across Europe and in the United States, particularly in relation to strategic assessments of first-in-human clinical trials with innovative research paths. Dr. Shi obtained her M.D. in China and also a Ph.D. in Medical Sciences from Vrije Universiteit Brussel. She has been appointed as a guest professor and visiting fellow in various universities worldwide. - 施琳达医学博士是远大医药中国有限公司（Grand Pharma）的副总裁兼首席医疗官，同时也是香港上市公司远大医药集团有限公司的执行董事。在2019年加入Grand Pharma之前，施博士在比利时杨森研发公司担任神经科学全球监管事务（GRA）欧盟监管负责人超过12年，在学术和制药行业拥有超过30年的临床和研究经验，具有与全球多功能矩阵团队合作推动复杂项目的丰富经验。她领导了欧洲和美国的各种临床试验申请（临床试验申请（CTA）和研究性新药申请（IND）），特别是与创新研究路径的首次人体临床试验的战略评估有关。施博士在中国获得医学博士学位，同时在布鲁塞尔自由大学获得医学博士学位。她被任命为全球多所大学的客座教授和客座研究员。
- Linda Shi M.D., Ph.D., is the deputy president and Chief Medical officer of Grand Pharma China Co. Ltd. (Grand Pharma), as well as an Executive Director of Grand Pharmaceutical Group Limited, a publicly listed company in Hong Kong. Prior to joining Grand Pharma in 2019 Dr. Shi was the EU Regulatory Leader in the Global Regulatory Affairs (GRA) for Neuroscience at Janssen R&D in Belgium for more than 12 years.has over 30 years of clinical and research experience in academic settings and the pharmaceutical industry, with significant experience working with global multifunctional matrixed teams to drive forward complex projects. She led various applications for clinical trials (Clinical Trial Applications (CTA) and Investigational New Drug Applications (IND)) across Europe and in the United States, particularly in relation to strategic assessments of first-in-human clinical trials with innovative research paths. Dr. Shi obtained her M.D. in China and also a Ph.D. in Medical Sciences from Vrije Universiteit Brussel. She has been appointed as a guest professor and visiting fellow in various universities worldwide.
- Robert H. Arch
-
Robert H. Arch自2021年7月起担任多家制药和生物技术公司的独立顾问。此前，Arch博士曾于2019年10月至2021年6月担任Elpiscience生物制药有限公司研究主管，并于2017年2月至2019年10月担任中国诺华生物医学研究院肝病部门主管。Arch博士的领导角色一直专注于组建强大的团队，并利用创新资产建立多元化的研发渠道，从创意到后期临床开发项目。Arch博士超过28年的职业生涯从学术界延伸到制药业，包括在诺华、武田、葛兰素史克和辉瑞任职。Arch博士在基础研究和药物开发方面的专长包括慢性肝病、癌症、免疫肿瘤学、呼吸系统疾病和炎症性疾病。Arch博士拥有德国维尔茨堡大学和德国癌症研究中心“DKFZ”，Heidelberg的博士学位。在DKFZ和芝加哥大学接受博士后培训后，Arch博士开始了他的独立职业生涯，在圣路易斯华盛顿大学的医学和病理学与免疫学系担任教员。Arch博士是40多种出版物和书籍章节的作者，也是临床阶段资产多项专利的共同发明人。
Robert H. Arch has served as an independent consultant to various pharmaceutical and biotechnology companies since July 2021. Previously, Dr. Arch served as Head of Research at Elpiscience Biopharma, Ltd. from October 2019 to June 2021 and Head of the Liver Disease Department at China Novartis Institutes for BioMedical Research from February 2017 to October 2019. Dr. Arch’s leadership roles have been focused on shaping strong teams and building diversified research and development pipelines with innovative assets, from ideas to late-stage clinical development programs. Dr. Arch’s career over 28 years extends from academia to the pharmaceutical industry, including positions at Novartis, Takeda, GlaxoSmithKline, and Pfizer. Dr. Arch’s expertise in basic research and drug development includes chronic liver disease, cancer, immuno-oncology, respiratory disease, and inflammatory disorders. Dr. Arch holds a Ph.D. in Germany from the University of Wuerzburg and the German Cancer Research Center the "DKFZ", Heidelberg. After postdoctoral training at the DKFZ and the University of Chicago, Dr. Arch started his independent career as a faculty member in the Departments of Medicine and Pathology & Immunology at Washington University in Saint Louis. Dr. Arch is an author on more than 40 publications and book chapters and co-inventor on several patents for clinical-stage assets. - Robert H. Arch自2021年7月起担任多家制药和生物技术公司的独立顾问。此前，Arch博士曾于2019年10月至2021年6月担任Elpiscience生物制药有限公司研究主管，并于2017年2月至2019年10月担任中国诺华生物医学研究院肝病部门主管。Arch博士的领导角色一直专注于组建强大的团队，并利用创新资产建立多元化的研发渠道，从创意到后期临床开发项目。Arch博士超过28年的职业生涯从学术界延伸到制药业，包括在诺华、武田、葛兰素史克和辉瑞任职。Arch博士在基础研究和药物开发方面的专长包括慢性肝病、癌症、免疫肿瘤学、呼吸系统疾病和炎症性疾病。Arch博士拥有德国维尔茨堡大学和德国癌症研究中心“DKFZ”，Heidelberg的博士学位。在DKFZ和芝加哥大学接受博士后培训后，Arch博士开始了他的独立职业生涯，在圣路易斯华盛顿大学的医学和病理学与免疫学系担任教员。Arch博士是40多种出版物和书籍章节的作者，也是临床阶段资产多项专利的共同发明人。
- Robert H. Arch has served as an independent consultant to various pharmaceutical and biotechnology companies since July 2021. Previously, Dr. Arch served as Head of Research at Elpiscience Biopharma, Ltd. from October 2019 to June 2021 and Head of the Liver Disease Department at China Novartis Institutes for BioMedical Research from February 2017 to October 2019. Dr. Arch’s leadership roles have been focused on shaping strong teams and building diversified research and development pipelines with innovative assets, from ideas to late-stage clinical development programs. Dr. Arch’s career over 28 years extends from academia to the pharmaceutical industry, including positions at Novartis, Takeda, GlaxoSmithKline, and Pfizer. Dr. Arch’s expertise in basic research and drug development includes chronic liver disease, cancer, immuno-oncology, respiratory disease, and inflammatory disorders. Dr. Arch holds a Ph.D. in Germany from the University of Wuerzburg and the German Cancer Research Center the "DKFZ", Heidelberg. After postdoctoral training at the DKFZ and the University of Chicago, Dr. Arch started his independent career as a faculty member in the Departments of Medicine and Pathology & Immunology at Washington University in Saint Louis. Dr. Arch is an author on more than 40 publications and book chapters and co-inventor on several patents for clinical-stage assets.
- Stephany Foster
-
Stephany Foster在会计和人力资源管理领域拥有20多年的经验。自2019年10月起，Foster女士担任QIAGEN N.V.首席人力资源官、高级副总裁、全球人力资源主管以及执行委员会成员，Sample to Insight解决方案的全球供应商，使客户能够从包含生命基石的样本中获得有价值的分子见解。在此之前，Foster女士于2019年1月起担任QIAGEN的薪酬和福利主管副总裁，此前于2005年1月至2018年12月担任QIAGEN的内部审计主管副总裁。Foster女士拥有圣母大学会计学学士和硕士学位。
Stephany Foster has over 20 years of experience in the fields of accounting and human resource management. Since October 2019 Ms. Foster has served as Chief Human Resources Officer, Senior Vice President, Head of Global Human Resources, and a member of the Executive Committee of QIAGEN N.V., a global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Prior to this position, Ms. Foster served as Vice President, Head of Compensation and Benefits, at QIAGEN from January 2019 and earlier as Vice President, Head of Internal Audit, at QIAGEN from January 2005 to December 2018. Ms. Foster holds both a Bachelor’s and Master’s degree in Accounting from the University of Notre Dame. - Stephany Foster在会计和人力资源管理领域拥有20多年的经验。自2019年10月起，Foster女士担任QIAGEN N.V.首席人力资源官、高级副总裁、全球人力资源主管以及执行委员会成员，Sample to Insight解决方案的全球供应商，使客户能够从包含生命基石的样本中获得有价值的分子见解。在此之前，Foster女士于2019年1月起担任QIAGEN的薪酬和福利主管副总裁，此前于2005年1月至2018年12月担任QIAGEN的内部审计主管副总裁。Foster女士拥有圣母大学会计学学士和硕士学位。
- Stephany Foster has over 20 years of experience in the fields of accounting and human resource management. Since October 2019 Ms. Foster has served as Chief Human Resources Officer, Senior Vice President, Head of Global Human Resources, and a member of the Executive Committee of QIAGEN N.V., a global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Prior to this position, Ms. Foster served as Vice President, Head of Compensation and Benefits, at QIAGEN from January 2019 and earlier as Vice President, Head of Internal Audit, at QIAGEN from January 2005 to December 2018. Ms. Foster holds both a Bachelor’s and Master’s degree in Accounting from the University of Notre Dame.
高管简历
中英对照 | 中文 | 英文- Robert H. Arch
Robert H. Arch自2021年7月起担任多家制药和生物技术公司的独立顾问。此前，Arch博士曾于2019年10月至2021年6月担任Elpiscience生物制药有限公司研究主管，并于2017年2月至2019年10月担任中国诺华生物医学研究院肝病部门主管。Arch博士的领导角色一直专注于组建强大的团队，并利用创新资产建立多元化的研发渠道，从创意到后期临床开发项目。Arch博士超过28年的职业生涯从学术界延伸到制药业，包括在诺华、武田、葛兰素史克和辉瑞任职。Arch博士在基础研究和药物开发方面的专长包括慢性肝病、癌症、免疫肿瘤学、呼吸系统疾病和炎症性疾病。Arch博士拥有德国维尔茨堡大学和德国癌症研究中心“DKFZ”，Heidelberg的博士学位。在DKFZ和芝加哥大学接受博士后培训后，Arch博士开始了他的独立职业生涯，在圣路易斯华盛顿大学的医学和病理学与免疫学系担任教员。Arch博士是40多种出版物和书籍章节的作者，也是临床阶段资产多项专利的共同发明人。
Robert H. Arch has served as an independent consultant to various pharmaceutical and biotechnology companies since July 2021. Previously, Dr. Arch served as Head of Research at Elpiscience Biopharma, Ltd. from October 2019 to June 2021 and Head of the Liver Disease Department at China Novartis Institutes for BioMedical Research from February 2017 to October 2019. Dr. Arch’s leadership roles have been focused on shaping strong teams and building diversified research and development pipelines with innovative assets, from ideas to late-stage clinical development programs. Dr. Arch’s career over 28 years extends from academia to the pharmaceutical industry, including positions at Novartis, Takeda, GlaxoSmithKline, and Pfizer. Dr. Arch’s expertise in basic research and drug development includes chronic liver disease, cancer, immuno-oncology, respiratory disease, and inflammatory disorders. Dr. Arch holds a Ph.D. in Germany from the University of Wuerzburg and the German Cancer Research Center the "DKFZ", Heidelberg. After postdoctoral training at the DKFZ and the University of Chicago, Dr. Arch started his independent career as a faculty member in the Departments of Medicine and Pathology & Immunology at Washington University in Saint Louis. Dr. Arch is an author on more than 40 publications and book chapters and co-inventor on several patents for clinical-stage assets.- Robert H. Arch自2021年7月起担任多家制药和生物技术公司的独立顾问。此前，Arch博士曾于2019年10月至2021年6月担任Elpiscience生物制药有限公司研究主管，并于2017年2月至2019年10月担任中国诺华生物医学研究院肝病部门主管。Arch博士的领导角色一直专注于组建强大的团队，并利用创新资产建立多元化的研发渠道，从创意到后期临床开发项目。Arch博士超过28年的职业生涯从学术界延伸到制药业，包括在诺华、武田、葛兰素史克和辉瑞任职。Arch博士在基础研究和药物开发方面的专长包括慢性肝病、癌症、免疫肿瘤学、呼吸系统疾病和炎症性疾病。Arch博士拥有德国维尔茨堡大学和德国癌症研究中心“DKFZ”，Heidelberg的博士学位。在DKFZ和芝加哥大学接受博士后培训后，Arch博士开始了他的独立职业生涯，在圣路易斯华盛顿大学的医学和病理学与免疫学系担任教员。Arch博士是40多种出版物和书籍章节的作者，也是临床阶段资产多项专利的共同发明人。
- Robert H. Arch has served as an independent consultant to various pharmaceutical and biotechnology companies since July 2021. Previously, Dr. Arch served as Head of Research at Elpiscience Biopharma, Ltd. from October 2019 to June 2021 and Head of the Liver Disease Department at China Novartis Institutes for BioMedical Research from February 2017 to October 2019. Dr. Arch’s leadership roles have been focused on shaping strong teams and building diversified research and development pipelines with innovative assets, from ideas to late-stage clinical development programs. Dr. Arch’s career over 28 years extends from academia to the pharmaceutical industry, including positions at Novartis, Takeda, GlaxoSmithKline, and Pfizer. Dr. Arch’s expertise in basic research and drug development includes chronic liver disease, cancer, immuno-oncology, respiratory disease, and inflammatory disorders. Dr. Arch holds a Ph.D. in Germany from the University of Wuerzburg and the German Cancer Research Center the "DKFZ", Heidelberg. After postdoctoral training at the DKFZ and the University of Chicago, Dr. Arch started his independent career as a faculty member in the Departments of Medicine and Pathology & Immunology at Washington University in Saint Louis. Dr. Arch is an author on more than 40 publications and book chapters and co-inventor on several patents for clinical-stage assets.
- George Chi
George Chi从THPlasma加入公司，自2020年7月起担任首席执行官，帮助公司创立了血浆采集业务并建立了常规的商业销售业务。在加入THPlasma之前，Chi先生曾于2018年9月至2020年2月在CASI制药公司担任Chief Financial Officer。CASI是一家专注于开发创新疗法和医药产品并将其商业化的生物制药公司。在加入CASI之前，池先生于2016年10月至2018年9月担任包装食品公司Flavors Holdings，Inc.的财务副总裁，负责全球会计职能，包括财务报告、规划、财务、投资者关系、税务和审计，在全球90个国家/地区拥有销售业绩。在2014年至2016年任职于Flavor Holdings，Inc.之前，Chi先生担任BPL Plasma的Chief Financial Officer，BPL Plasma是一家大型第三方血浆采集企业。2008年至2013年，池先生在Unilever PLC担任财务总监，负责领导会计职能，包括财务报告、年度预算编制和战略规划。迟先生拥有中国北京清华大学工程学士学位和耶鲁大学管理学院金融与运营工商管理硕士学位。他还拥有注册会计师和CFA证书。
George Chi joined the Company from THPlasma, where he served as Chief Executive Officer since July 2020 and helped found the company’s plasma collection business and establish regular commercial sales. Prior to joining THPlasma, Mr. Chi served as Chief Financial Officer of CASI Pharmaceuticals, Inc. "CASI", a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, from September 2018 to February 2020. Prior to joining CASI, Mr. Chi was Vice President of Finance at Flavors Holdings, Inc., a packaged food company, from October 2016 to September 2018 where he led the global accounting function, including financial reporting, planning, treasury, investor relations, tax and auditing with global sales in 90 countries. Prior to his time at Flavor Holdings, Inc. from 2014-2016 Mr. Chi was Chief Financial Officer at BPL Plasma, a large third party blood plasma collection business. From 2008-2013 Mr. Chi was finance director at Unilever PLC where he was responsible for leading the accounting function including financial reporting, annual budgeting and strategic planning. Mr. Chi holds a bachelor’s degree in engineering from Tsinghua University, Beijing, China and a M.B.A. in finance and operations from the Yale School of Management. He also holds certifications as a CPA and CFA.- George Chi从THPlasma加入公司，自2020年7月起担任首席执行官，帮助公司创立了血浆采集业务并建立了常规的商业销售业务。在加入THPlasma之前，Chi先生曾于2018年9月至2020年2月在CASI制药公司担任Chief Financial Officer。CASI是一家专注于开发创新疗法和医药产品并将其商业化的生物制药公司。在加入CASI之前，池先生于2016年10月至2018年9月担任包装食品公司Flavors Holdings，Inc.的财务副总裁，负责全球会计职能，包括财务报告、规划、财务、投资者关系、税务和审计，在全球90个国家/地区拥有销售业绩。在2014年至2016年任职于Flavor Holdings，Inc.之前，Chi先生担任BPL Plasma的Chief Financial Officer，BPL Plasma是一家大型第三方血浆采集企业。2008年至2013年，池先生在Unilever PLC担任财务总监，负责领导会计职能，包括财务报告、年度预算编制和战略规划。迟先生拥有中国北京清华大学工程学士学位和耶鲁大学管理学院金融与运营工商管理硕士学位。他还拥有注册会计师和CFA证书。
- George Chi joined the Company from THPlasma, where he served as Chief Executive Officer since July 2020 and helped found the company’s plasma collection business and establish regular commercial sales. Prior to joining THPlasma, Mr. Chi served as Chief Financial Officer of CASI Pharmaceuticals, Inc. "CASI", a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, from September 2018 to February 2020. Prior to joining CASI, Mr. Chi was Vice President of Finance at Flavors Holdings, Inc., a packaged food company, from October 2016 to September 2018 where he led the global accounting function, including financial reporting, planning, treasury, investor relations, tax and auditing with global sales in 90 countries. Prior to his time at Flavor Holdings, Inc. from 2014-2016 Mr. Chi was Chief Financial Officer at BPL Plasma, a large third party blood plasma collection business. From 2008-2013 Mr. Chi was finance director at Unilever PLC where he was responsible for leading the accounting function including financial reporting, annual budgeting and strategic planning. Mr. Chi holds a bachelor’s degree in engineering from Tsinghua University, Beijing, China and a M.B.A. in finance and operations from the Yale School of Management. He also holds certifications as a CPA and CFA.